A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Minocycline rescued synaptic abnormalities and improved behavior in the fragile X mouse model. Previous open-label human studies demonstrated benefits in individuals with fragile X syndrome (FXS); however, its efficacy in patients with FXS has not been assessed in a controlled trial. METHOD: Randomized, double-blind, placebo-controlled, crossover trial in individuals with FXS, aged 3.5 years to 16 years (n = 55, mean age 9.2 [SD, 3.6] years). Participants were randomized to minocycline or placebo for 3 months and then switched to the other treatment. RESULTS: Sixty-nine subjects were screened and 66 were randomized. Fifty-five subjects (83.3%) completed at least the first period and 48 (72.7%) completed the full trial. Intention-to-treat analysis demonstrated significantly greater improvements in one primary outcome, Clinical Global Impression Scale-Improvement after minocycline compared with placebo (2.49 ± 0.13 and 2.97 ± 0.13, respectively, p = .0173) and greater improvement in ad hoc analysis of anxiety and mood-related behaviors on the Visual Analog Scale (minocycline: 5.26 cm ± 0.46 cm, placebo: 4.05 cm ± 0.46 cm; p = .0488). Side effects were not significantly different during the minocycline and placebo treatments. No serious adverse events occurred on minocycline. Results may be potentially biased by study design weaknesses, including unblinding of subjects when they completed the study, drug-related side effects unblinding, and preliminary efficacy analysis results known to investigators. CONCLUSIONS: Minocycline treatment for 3 months in children with FXS resulted in greater global improvement than placebo. Treatment for 3 months appears safe; however, longer trials are indicated to further assess benefits, side effects, and factors associated with a clinical response to minocycline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reduction of MMP-9 levels with minocycline in humans with FXS (Dziembowska et al., 2013) contributes to reversal of several FXS phenotypes, including behavioral deficits and enhanced auditory electrocortical activity in adults and/or adolescents with FXS (Paribello et al., 2010; Leigh et al., 2013; Schneider et al., 2013).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Leigh et al., 2013
Experimental — accuracy not yet measuredIn the citing paper
“In a randomized double-blind, placebo-controlled trial in children and adolescents with FXS, three months of minocycline treatment improved anxiety and mood-related behaviours238.”
From Immune mediators in the brain and peripheral tissues in autism spectrum disorder (2015) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wechsler Abbreviated Scale of Intelligence
Dumont, R., Willis, J. O., Veizel, K., & Zibulsky, J. (2014) · Encyclopedia of Special Education · doi:10.1002/9781118660584.ese2519 · Cited by 5,521
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Mullen Scales of Early Learning
Bradley-Johnson, S. (1997) · Psychology in the Schools · doi:10.1002/(sici)1520-6807(199710)34:4<379::aid-pits14>3.0.co;2-e · Cited by 2,325
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072
Stanford-Binet Intelligence Scale
(2012) · SpringerReference · doi:10.1007/springerreference_70151 · Cited by 1,664
Yrjänheikki, J., Tikka, T., Keinänen, R., Goldsteins, G., Chan, P. H., & Koistinaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,038
Dumont, R., & Willis, J. O. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0804 · Cited by 946
de Boer, A. G. E. M., van Lanschot, J. J. B., Stalmeier, P. F. M., van Sandick, J. W., Hulscher, J. B. F., de Haes, J. C. J. M., & Sprangers, M. A. G. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018499.64574.1f · Cited by 743
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Self-citationBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465
Research works printed but not linked: 1
- Sparrow SS Cicchetti DV Balla DA Vineland Adaptive Behavior Scales 2005 American Guidance Service Circle Pines Second Edition
Cited by
Items 201–297 of 297
Mechanism-Based Therapy of Genetic Neurological Disease
Roach, E. S. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.01.042 · Cited by 3
Steenbergen, A. V., Kaur, M., Rubanarayana, K., & Bolduc, F. V. (2026) · Neurology Genetics · doi:10.1212/nxg.0000000000200373 · Cited by 2
“23,30 These fi ndings underscore the potential importance of early intervention, and future studies should examine the long-term impact of early treatment on symptom progression in FXS. Distinct developmental stages, baseline behaviors, and adaptive functioning likely in fl uence responsiveness to…”
Ours, C., Hodges, M. B., Oden, N. L., Sapp, J. C., & Biesecker, L. G. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02325-6 · Cited by 2
Fragile X clinical features and neurobiology
Leigh, M. J., & Hagerman, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814409-1.00015-x · Cited by 2
Self-citationBekheet, M., Mansour, L. A., Elkaffas, R. H., Kamel, M. A., & Elmonem, M. A. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110659 · Cited by 2
Fragile X Syndrome and Premutation‐Associated Disorders
Hagerman, R. J. (2010) · Wiley eBooks · doi:10.1002/9780470893159.ch27 · Cited by 3
Self-citationExpansion and Implications of Newborn Screening
Rajabi, F., & Levy, H. L. (2015) · Current Genetic Medicine Reports · doi:10.1007/s40142-015-0070-1 · Cited by 2
“In progress are clinical trials of minocycline with potential cognitive and behavioral benefits, and arbaclofen that might confer improvement in social function [45, 46].”
BackgroundReflections on Clinical Trials in Fragile X Syndrome
Jønch, A. E., & Jacquemont, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00020-2 · Cited by 2
Matrix Metalloproteinases in Fragile X Syndrome
Ethell, D. W., & Sidhu, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00015-9 · Cited by 2
Hare, E. B., Lozano, R., Partington, L. C., & Hagerman, R. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-18096-0_64 · Cited by 2
Self-citationMetformin treatment in young children with fragile X syndrome
Biag, H. M. B., La, P., & Wilkins, E. A. (2020) · Yearbook of pediatric endocrinology · doi:10.1530/ey.17.12.8 · Cited by 1
Oligodendroglia and myelin pathology in fragile X syndrome
Hourani, S., & Pouladi, M. A. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16144 · Cited by 1
“…its activity pharmacologically alleviates key physiological and behavioral FXS phenotypes, including dendritic spine abnormalities, anxiety, and overall cognition (Bilousova et al., 2009; Leigh et al., 2013; Paribello et al., 2010; Rotschafer et al., 2012; Sidhu et al., 2014; Utari et al., 2010).”
Indonesian Scholars' Contributions to Global Psychology: A Bibliometric Study
Siaputra, I. B., Abraham, J., & Ho, Y. (2024) · ANIMA Indonesian Psychological Journal · doi:10.24123/aipj.v39i2.6661 · Cited by 1
Protic, D. D., Stojković, M., & Budimirovic, D. B. (2025) · Medicinska istrazivanja · doi:10.5937/medi0-60213 · Cited by 1
mRNA Translation and Proteasomal Degradation in Health and Neurological Disease
Isaac, A. R., Cozachenco, D., Wagner, B. D. A., Chauvet, M. G., & Lourenco, M. V. (2026) · Physiology · doi:10.1152/physiol.00023.2025 · Cited by 1
A Male with Cooccurrence of Down Syndrome and Fragile X Syndrome
Anderson, T., Buterbaugh, A., Love, K. M., & Visootsak, J. (2013) · Case Reports in Genetics · doi:10.1155/2013/504695 · Cited by 1
Síndrome X frágil y otras patologías asociadas al gen FMR1
Juárez, J. C. C., de León, M. J. Z., Díaz, D. J. S., Alvarado, C. G. B., García, D. A. S., & Arévalo, G. S. (2021) · Revista Med · doi:10.18359/rmed.5262 · Cited by 3
Goumalatsou, C. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0001 · Cited by 1
Clutton, J. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0008 · Cited by 1
Clutton, J. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0007 · Cited by 1
Myers, G. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0012 · Cited by 1
Pre-hospital emergency medicine
Collingwood, T. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0010 · Cited by 1
Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations
Hagerman, R. J., Narcisa, V., & Hagerman, P. J. (2009) · Wiley eBooks · doi:10.1002/9781444314342.ch9
Self-citationKamm, C. (2013) · Clinical Investigation · doi:10.4155/cli.13.45
Therapiekonzepte bei genetischen Syndromen mit mentaler Retardierung
Omran, H., Kunde-Trommer, J., & Blank, R. (2014) · Elsevier eBooks · doi:10.1016/b978-3-437-23076-9.00003-6
Microglial Abnormalities in the Pathophysiology of
Monji, S., Mizoguchi, Y., & Kato, T. A. (2014) · Cited by 1
Effects of Sertraline Treatment for Young Children with FXS
Hess, L. G., Mundy, P. C., & Hagerman, R. J. (2015) · Dominican Scholar (Dominican University of California)
Self-citationFragile X Syndrome: Rx Minocycline?
Stein, M. T. (2013) · Journal watch · doi:10.1056/pa201305010000003
de Diego‐Otero, Y., Pérez-Costillas, L., Medina, R. C., Quintero-Navarro, C., Benítez, I. D. P., Casado, Y., & Cobas, C. N. (2017) · Revista Española de Discapacidad · doi:10.5569/2340-5104.05.01.12 · Cited by 1
Modelling fragile X syndrome in rats: new directions in translational research
Asiminas, A. (2017) · ERA · Cited by 1
Identifying barriers to clinical trial participation with families affected by fragile X syndrome
Eley, S. E. A. (2017) · Edinburgh Research Archive (University of Edinburgh)
Steventon, N. B. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.003.0005
Baldwin, A., & Myers, G. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0015
Muscle, Connective Tissue, and Neonatal Disorders
(2019) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-5225-8066-9.ch017
Muscle, Connective Tissue, and Neonatal Disorders
Wambuguh, O. J. (2022) · IGI Global eBooks · doi:10.4018/978-1-6684-5360-5.ch009
Mielke, B. (2014) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4833
Arianayagam, S. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0006
Baldwin, A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0013
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0006
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0004
Buckley, S. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0003
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0002
Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations
Hagerman, R. J., & Hagerman, P. J. (2021) · Wiley eBooks · doi:10.1002/9781119676980.ch16
Self-citationBaldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0008
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0003
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0001
Baldwin, A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.003.0014
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0009
Fragile X clinical features and neurobiology
Leigh, M. J., & Hagerman, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00022-2
Self-citationBaldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0012
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0014
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0010
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0007
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0013
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0005
Hollander, E., & Uzunova, G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738414892.793578080
Goumalatsou, C. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0002
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0011
Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations
Hagerman, R. J., & Hagerman, P. J. (2015) · Wiley eBooks · doi:10.1002/9781118981559.ch7
Self-citationDenniston, A. K., & Mathewson, P. A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0004
Hjelde, N. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0011
Graham, B. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0009
Fragile X-associated disorders
Hagerman, R. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00037-x
Self-citation(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0004
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0010
JABC, & JML (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0008
Baldwin, A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0007
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0002
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0003
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0011
Reference intervals—biochemistry
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.002.0012
Reference intervals—haematology
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.002.0013
Chapter 65. Treatment of Individuals With Intellectual Developmental Disorder
Stratigos, K. A., Katz, J., & Hong, D. S. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as65
Fragile X clinical features and neurobiology
Leigh, M. J., & Hagerman, R. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00036-4
Self-citationOlatomide, O. D., Emmanuel, C. T., Arogundade, T. T., Alake, T. G., Idowu, O. D., Akin-Adekeye, U. T., Tawose, O. M., Omotoso, D. R., Ajayi, O. F., & Oguntimehin, B. M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5399288
The endocannabinoid system in intellectual disability
Vázquez-Oliver, A., Reyes‐Ramírez, L. D. L., Galera-López, L., & Ozaita, A. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00022-0
Gene delivery by sonoporation for Fragile X syndrome therapy
Ador, T. (2025) · theses.fr (ABES) · doi:10.70675/c662294bz7988z4047zb5f8z9345432e2d0e
Ours, C., Hodges, M. B., Oden, N. L., Sapp, J. C., & Biesecker, L. G. (2022) · Figshare · doi:10.6084/m9.figshare.19646206
Bases moléculaires de la physiopathologie du syndrome de l'X fragile
Tabet, R. (2013) · theses.fr (ABES) · doi:10.70675/0e233978z1479z4a80zaa6az60107c0a5c0d
Dissecting the role of calcium signaling in Fragile X syndrome
Castagnola, S. (2019) · theses.fr (ABES) · doi:10.70675/3d35096bz79d0z46edz8a70zb783a8f60257
Felgerolle, C. (2019) · theses.fr (ABES) · doi:10.70675/fbd5cf69zed5az4a57zbfdez48e26a937a72
Pathophysiological consequences of a Fragile X missense mutation
Garcia, M. P. (2020) · theses.fr (ABES) · doi:10.70675/b8e86263z5926z4a83zbaf6z0f61bf2d15f9
Tetracycline antibiotics: Emerging roles in neuropsychiatric disorders
Acar, A. Ş., Saday, Ö., & Erbaş, O. (2024) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2024.149
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0005
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0010
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0008
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0015
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0003
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0002
JABC, & JML (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0006
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0011
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0012
Open-label clinical trial of lovastatin and minocycline combined treatment in fragile X syndrome
Champigny, C. M. (2018) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
Olatomide, O. D., Emmanuel, C., Arogundade, T. T., Alake, T. G., Idowu, O. D., Akin-Adekeye, U. T., Tawose, O. M., Ajayi, O. F., Oguntimehin, B. M., Adeyinka, Q. I., et al. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2751095
Metadata
- Authors
- Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., Hessl, D., & Hagerman, R. J.
- Affiliations
- University of California Davis Medical Center (US)
- University of California, Davis (US)
- Diponegoro University (ID)
- Corresponding author
- Leigh, Mary Jacena S.
- Schneider, Andrea
- Chechi, Tasleem
- Polussa, Jonathan
- Hessl, David
- Hagerman, Randi J.
- ORCID
- Venue
- Journal of Developmental & Behavioral Pediatrics
- Published
- 2013-04
- Volume
- 34
- Issue
- 3
- Pages
- 147-155
- ISSN
- 0196-206X (ISSN-L)
- PMC
- PMC3706260
- OpenAlex
- W2159857276
- Cited by
- 298
- References
- 37
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 12 · 2023: 7 · 2022: 18 · 2021: 10 · 2020: 48 · 2019: 21 · 2018: 19 · 2017: 35 · 2016: 40 · 2015: 28 · 2014: 32 · 2013: 15
- FWCI
- 25.44
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Developmental & Behavioral Pediatrics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000002)
- University of California, Davis
- National Institute of Mental Health (T32MH073124)
- National Center for Research Resources (UL1RR024146)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 02274, P30HD002274)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Developmental Neuroscience › Williams Syndrome Research
- Keywords
- minocycline, fragile X syndrome, children and adolescents, anxiety, mood, Clinical Global Impression Scale, treatment efficacy, drug safety, synaptic abnormalities
- MeSH terms
- Adolescent, Child, Child, Preschool, Double-Blind Method, Female, Fragile X Syndrome, Humans, Intelligence, Male, Minocycline, Psychiatric Status Rating Scales, Psychological Tests, Treatment Outcome, Cross-Over Studies, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.